Enabled Therapeutics

Executive Summary

Enabled Therapeutics is a pre-clinical biotechnology company pioneering a novel class of redox-activated small-molecule prodrugs called Captons®. These prodrugs are designed to remain inert in healthy tissues but selectively activate in diseased microenvironments characterized by oxidative stress and inflammation, such as those found in neurodegenerative disorders. The company’s lead focus is on Alzheimer’s disease, an area of high unmet need, but the platform has potential applicability to other CNS conditions including acute injuries and chronic neurodegeneration. By leveraging a unique activation mechanism, Captons aim to improve the therapeutic index of existing and novel small molecules, potentially reducing systemic toxicity while enhancing efficacy at the site of pathology. The company is currently in the pre-clinical stage, conducting IND-enabling studies for its lead candidate. While specific pipeline details are limited, the company’s technological approach differentiates it from conventional CNS drug development. Key near-term milestones are expected to include completion of GLP toxicology studies, filing of an Investigational New Drug (IND) application, and securing additional financing (e.g., Series A round) to advance into clinical trials. Given the early stage, risk remains high, but the platform’s innovative design and alignment with biomarkers of disease pathology provide a compelling rationale for further development.

Upcoming Catalysts (preview)

• Q2 2027IND Filing for Lead Alzheimer's Candidate30% success
• Q4 2026Series A Financing Round50% success
• Q1 2027Presentation of Preclinical Data at Major Conference70% success